Ironwood Pharmaceuticals/$IRWD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Ticker
$IRWD
Sector
Primary listing
Employees
253
Headquarters
Website
IRWD Metrics
BasicAdvanced
$548M
19.03
$0.18
0.26
-
Price and volume
Market cap
$548M
Beta
0.26
52-week high
$5.13
52-week low
$0.53
Average daily volume
3.3M
Financial strength
Current ratio
1.129
Quick ratio
1.075
Long term debt to equity
-149.721
Total debt to equity
-226.471
Interest coverage (TTM)
4.26%
Profitability
EBITDA (TTM)
145.676
Gross margin (TTM)
101.54%
Net profit margin (TTM)
8.42%
Operating margin (TTM)
42.41%
Effective tax rate (TTM)
69.49%
Revenue per employee (TTM)
$1,340,000
Management effectiveness
Return on assets (TTM)
22.88%
Return on equity (TTM)
-9.92%
Valuation
Price to earnings (TTM)
19.029
Price to revenue (TTM)
1.603
Price to book
-2.08
Price to tangible book (TTM)
-2.06
Price to free cash flow (TTM)
8.031
Free cash flow yield (TTM)
12.45%
Free cash flow per share (TTM)
0.42
Growth
Revenue change (TTM)
-10.42%
Earnings per share change (TTM)
-1,083.97%
3-year revenue growth (CAGR)
-6.93%
10-year revenue growth (CAGR)
9.70%
3-year earnings per share growth (CAGR)
-42.67%
10-year earnings per share growth (CAGR)
-17.25%
What the Analysts think about IRWD
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
IRWD Financial Performance
Revenues and expenses
IRWD Earnings Performance
Company profitability
IRWD News
AllArticlesVideos
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
Business Wire·1 month ago
Google's AI chip 'Ironwood' takes on Nvidia
CNBC Television·1 month ago
Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals (IRWD) has a market cap of $548M as of December 18, 2025.
What is the P/E ratio for Ironwood Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ironwood Pharmaceuticals (IRWD) stock is 19.03 as of December 18, 2025.
Does Ironwood Pharmaceuticals stock pay dividends?
No, Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders as of December 18, 2025.
When is the next Ironwood Pharmaceuticals dividend payment date?
Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders.
What is the beta indicator for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals (IRWD) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.